A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer

Introduction: Androgen deprivation therapy (ADT) with androgen receptor axis-targeted (ARAT) is the standard of care provided to patients metastatic prostate cancer. While effective, it results in sequelae, such as loss skeletal muscle mass. In this study, we compared sarcopenic effects abiraterone and enzalutamide, two ARATs used treat Methods: Our cohort comprised 55 diagnosed hormone-naive cancer from 2014–2019. Patients were divided into three treatment groups: gonadotropin-releasing hormone (GnRH) agonist alone; GnRH combined acetate; enzalutamide. We then axial computed tomographic (CT) scans at L3 level before after initiation for each patient. A index (SMI) was calculated patient, alongside clinical data, between groups. One-way analysis variance (ANOVA) Fisher’s exact test compare means proportions, respectively. Results: Baseline characteristics not significantly different The percent SMI change number newly found be only variable that across groups time CT scans. Conclusions: Although no significant difference alone, or enzalutamide our patients, overall decreases mass observed all This highlights importance muscle-retaining strategies undergoing ADT cancer, regardless therapeutic regimen.